BIOMAT Database Logo BIOMAT Database Logo

Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). 1991

T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Research Laboratory, Zenyaku Kogyo Co., Ltd., Tokyo, Japan.

We studied bioavailability, treatment schedule dependence, and therapeutic efficacy of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine), against murine tumors and human tumor xenografts. The rate of its intestinal absorption was about 50%, and it was immediately metabolized to its parent compound, ICRF-154. Therapeutic efficacy of MST-16 was heavily dependent on the treatment schedule: 9 daily oral administrations and treatment every 4 h on day 1 only were much more effective against s.c.-implanted L1210 leukemia than a single dose or five daily administrations giving the same total dose. Orally administered MST-16 showed potent life-prolonging effects (196%, 219% and 148%) in mice inoculated i.p. with P388, L1210 leukemia, and C-26 colon adenocarcinoma, respectively, but had no effect on B16 melanoma inoculated in the same way. MST-16 inhibited more than 80% growth of Lewis lung carcinoma, B16 melanoma, and C-38 colon adenocarcinoma implanted s.c., but had only a minor effect on M5076 fibrosarcoma. Lung metastasis of Lewis lung carcinoma was also effectively suppressed. Furthermore, MST-16 significantly inhibited growth of human colon, lung and breast cancers implanted s.c. in nude mice. We also made a kinetic analysis of the in vitro cell-killing effect by ICRF-154, the active form of MST-16 in vivo. It demonstrated a cell cycle phase-specific and time-dependent action, providing a reasonable explanation for the schedule-dependent therapeutic effect of MST-16.

UI MeSH Term Description Entries
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines.
January 1998, Cancer chemotherapy and pharmacology,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
January 1990, Cancer chemotherapy and pharmacology,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group.
April 1993, Cancer,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
December 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
September 1991, Cancer research,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine).
March 1992, Journal of the National Cancer Institute,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
[A novel antitumor agent, sobuzoxane (MST-16)].
June 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Dioxopiperazine derivative potentiates antitumor effect of methylglyoxal bis(cyclopentylamidinohydrazone) on human and mouse leukemia cells.
January 1994, Anticancer research,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
Antitumor and antimicrobial activities of enterococcal preparation orally administered to mice.
June 1993, Annals of the New York Academy of Sciences,
T Narita, and Y Koide, and S Yaguchi, and S Kimura, and Y Izumisawa, and M Takase, and M Inaba, and S Tsukagoshi
[Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
March 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!